companydata.dkcompanydata.dk

VELOXIS PHARMACEUTICALS A/S: Financial statements 2024

CVR: 26527767

Source: annual report 2024, Danish Business Authority

01/04/2023 – 31/03/2024

VELOXIS PHARMACEUTICALS A/S (CVR 26527767) has filed annual accounts for 2024. Equity in the 2024 report amounted to USD -10,491,000. The company had 1 employee in the financial year.

Equity
USD -10,491,000
Total Assets
USD 3,326,000
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024----10.5M USD1
2023---2.8M USD1
20220 USD0 USD2.1M USD2.9M USD-
202145.3M USD45.3M USD1.1B USD1.3B USD-
201839.5M USD31.6M USD-5.3M USD4.6M USD-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Daisuke Matsuo joins VELOXIS PHARMACEUTICALS A/S as adm. dir.Oct 9, 2024

As of October 9, 2024, Daisuke Matsuo is registered as adm. dir. of VELOXIS PHARMACEUTICALS A/S.

Mark Earl Hensley steps down as adm. dir. of VELOXIS PHARMACEUTICALS A/SOct 8, 2024

As of October 8, 2024, Mark Earl Hensley has stepped down as adm. dir. of VELOXIS PHARMACEUTICALS A/S.

About VELOXIS PHARMACEUTICALS A/S

VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named LIFECYCLE PHARMA A/S and PHAROTECH A/S. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 1 employee (2022). In 2026, the company reported a net result of DKK -1,553,000. Equity in the 2026 report amounted to DKK 611,587,000.

Source: annual report 2026, Danish Business Authority